Using the TipRanks Highest P/E Ratio Stocks tool, we identified three companies with high price-to-earnings (P/E) ratios and more than 40% upside potential over the next 12 months, making them attractive opportunities for growth-focused investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Let’s dive into the details.
Why High P/E Stocks
An investment’s real value lies in its expected future growth. High P/E ratios might signal overpricing at first glance, but they often reflect strong optimism for rapid earnings expansion. The key is benchmarking current prices against projected growth paths. Investing in high P/E stocks is essentially wagering on companies with solid fundamentals, ongoing innovation, and expanding markets.
Palantir (PLTR)
- P/E Ratio: 100.6x
- Average Palantir’s Stock Price Target: $188.31 (44.80% upside)
Palantir Technologies is a data analytics and AI software company that helps governments and businesses analyze large and complex datasets. The stock currently trades at a P/E ratio close to 100x, making it one of the priciest software stocks in the market.
Palantir recently reported strong Q1 2026 results, but the stock still faced pressure as investors worried about its high valuation. Looking ahead, analysts remain moderately bullish on PLTR stock, supported by strong demand for the company’s AI-driven software platforms, though valuation concerns continue to limit upside sentiment.
Kratos Defense (KTOS)
- P/E Ratio: 242.5x
- Average Kratos Defense Price Target: $104.54 (101.19% upside)
Kratos is a defense technology company that develops drones, satellite systems, cybersecurity tools, and other missile defense products for the U.S. government and allied nations. KTOS trades at a high P/E ratio mainly because investors expect strong future growth. The market is betting that rising global defense spending could significantly increase Kratos’ revenue and profits over the next several years. As a result, investors are willing to pay a premium valuation today in anticipation of faster long-term growth.
Looking ahead, analysts are bullish with a Strong Buy rating, backed by 11 Buys and three Holds assigned in the last three months.
Alnylam Pharma (ALNY)
- P/E Ratio: 53.0x
- Average Alnylam Pharma Stock Price Target: $449.12 (52.7% upside)
Alnylam is a biotechnology company focused on developing RNA interference (RNAi) therapies, a technology designed to silence disease-causing genes. The company develops treatments for rare genetic diseases and other serious conditions, with several approved drugs already on the market.
The market is betting that Alnylam’s RNAi technology could lead to more blockbuster treatments and larger revenue streams in the future. As a result, Alnylam tends to trade at premium valuations as investors expect rapid sales growth, new drug approvals, or breakthroughs in medical technology.
Looking ahead, analysts are bullish on ALNY stock with a Strong Buy rating, backed by 16 Buys and four Holds assigned in the last three months.